CFAP96 and prostate cancer: However, glioma, thyroid cancer, colorectal cancer, liver cancer, kidney cancer, prostate cancer, testicular cancer, and melanoma (Supplementary Fig. b) showed significantly worse prognosis in the high C4orf47-expressing group.